BETA
Manufacturer of TRUE-branded and co-branded blood glucose monitoring systems and diabetes-care devices.
Trividia Health, Inc. develops, manufactures and markets blood glucose monitoring systems and related diabetes-care devices. It is headquartered in Fort Lauderdale, Florida, and reports manufacturing operations in Florida, New Hampshire and Taiwan.
Products are marketed under the TRUE brand and under retailer or distribution-partner brands. Selected device families include TRUE METRIX blood glucose monitoring systems and TRUEdraw lancing devices. Total Diabetes Supply is treated separately as a retailer, rather than as the manufacturer identity.
The company has documented FDA clearances as well as recall activity affecting particular devices and labeling. The regulatory section distinguishes current manufacturer correction information from the status reported in FDA recall records.
The selected portfolio has documented FDA clearances for TRUE METRIX and TRUE METRIX GO glucose monitoring systems and TRUEdraw lancing devices. K140100 is a legacy Nipro Diagnostics record linked to current TRUE METRIX products by FDA recall records; clearance scope is specific to the reviewed device versions. [2][4][3][1]
FDA’s April 28, 2026 safety communication, updated May 19, addresses E-5 error-code risks across affected TRUE METRIX, AIR, GO and PRO systems, including co-branded products. FDA recommends transition to an alternative testing method when possible, without stopping glucose testing before an alternative is available. Consult the FDA communication for the full recommendations. [14]
At this review, Trividia’s product page reports corrected meter software and revised instructions distinguishing E-5 from EHi. This manufacturer update does not establish that all affected units have been corrected or that FDA has terminated the recall. [17]
The scoped records also include an open 2025 Good Neighbor Pharmacy meter recall for display defects and a terminated 2020 meter-packaging event. An older TRUEread strip event remains recorded as open in the retrieved FDA feed, but its mapping to the current portfolio is unresolved and it is excluded from current-portfolio counts. [11][9][7][5]
Latest recorded source review: 2026-10-28.
Includes open events outside the mapped current portfolio; those events are excluded from the snapshot count.
| Recalled product / record | Initiated | Source |
|---|---|---|
| February 6, 2026 | [11][12] |
| October 7, 2025 | [9][10] |
| June 28, 2016 | [5][6] |
Documented commercial product families.
Meter-and-test-strip systems for blood glucose measurement, including TRUE METRIX, AIR and GO formats and co-branded variants. [17][2][4][1]
FDA-clearedListed by the company; configurations and market availability vary.
Adjustable-depth, single-patient lancing device used with compatible lancets to obtain a blood sample. [18][3]
FDA-clearedListed by the company; configurations and market availability vary.
FDA issued K262116 for a TRUE METRIX self-monitoring blood glucose system; the decision is separate from termination of any recall. [4]
Accessed 10/28/2026